{"id":16118,"name":"AGE1","slug":"age1","website":"https://age1.com/","hqGeo":null,"stageFocus":["Pre-Seed","Seed"],"sectorTags":["Healthcare","AI / ML","Consumer"],"excludedSectors":[],"checkSizeMin":null,"checkSizeMax":null,"thesisSummary":"An earliest-stage longevity biotech solo-GP fund backing contrarian founders building therapeutics and tools to extend healthy lifespan and treat age-related disease. It is highly specialized but more biotech-heavy than consumer-facing.","thesisNarrative":null,"logoUrl":null,"aumUsd":null,"submissionUrl":null,"linkedinUrl":null,"twitterHandle":null,"portfolio":[{"companyName":"Conception Bio","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Turning stem cells into human eggs to reimagine family planning","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Loyal","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Healthspan and lifespan extension for dogs","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"NewLimit","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Reprogramming the epigenome to add healthy years to human life","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Precision Bioscience","companyUrl":null,"stage":null,"sector":"EXITED: IPO","investmentYear":null,"description":"Novel gene editing technology to develop new class of medicines","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Reservoir Neuroscience","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Therapeutics to heal the blood-brain barrier","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Skeletalis","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Targeted therapies for bone regeneration to treat age-related bone loss","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Stealth","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Developing the first human aging drugs","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"General Control","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Multiplex-editing therapies to target age-related disease","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Until Labs","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Cryopreservation technology for tissues and organs to end organ supply shortages","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Bexorg","companyUrl":null,"stage":"Not clearly stated","sector":"Biotechnology / neuroscience tools","investmentYear":null,"description":"Neuroscience and drug discovery company focused on human brain preservation and research models.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Rubedo Life Sciences","companyUrl":null,"stage":"Not clearly stated","sector":"Biotechnology / senolytics","investmentYear":null,"description":"Develops medicines that selectively target senescent cells.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"ALX Oncology","companyUrl":null,"stage":null,"sector":"EXITED: IPO","investmentYear":null,"description":"First-in-class foundational checkpoint immunotherapies","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Arda Therapeutics","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Targeting pathogenic cells to treat aging and chronic diseases","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Decibel Therapeutics","companyUrl":null,"stage":null,"sector":"EXITED: IPO","investmentYear":null,"description":"Regenerative and gene therapies to restore hearing and balance","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Unity Biotechnology","companyUrl":null,"stage":null,"sector":"EXITED: IPO","investmentYear":null,"description":"Therapeutics to slow, halt, or reverse diseases of aging","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Gordian Biotechnology","companyUrl":null,"stage":"Not clearly stated","sector":"Biotechnology / gene therapy platform","investmentYear":null,"description":"Builds gene-therapy platforms for in vivo drug discovery.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Aperture Therapeutics","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Next-generation interventions to cure neurodegeneration and delay brain aging","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Deciduous Therapeutics","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Activation of the endogenous immune system for eliminating pathogenic cells","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Metacrine","companyUrl":null,"stage":null,"sector":"EXITED: IPO","investmentYear":null,"description":"Therapies for gastrointestinal and liver disease","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Navitor","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Platform for therapeutics targeting mTORC1","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Science Corporation","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Redefining human capabilities with advanced medical technology","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Conception","companyUrl":null,"stage":"Not clearly stated","sector":"Reproductive biotech","investmentYear":null,"description":"Works on reproductive and fertility technology.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Spring Discovery","companyUrl":null,"stage":"Not clearly stated","sector":"Biotechnology / AI drug discovery","investmentYear":null,"description":"AI-enabled drug discovery company.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Aerska","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Precision therapeutics for genetic forms of neurodegeneration","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Fauna Bio","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"AI-led drug discovery engine translating conserved pathways of disease resistance across species","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"General Proximity","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Next generation of induced proximity medicines","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Gordian Bio","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Pooled in vivo platform for new therapeutics tackling complex age-related disease","amountUsd":null,"relevanceNote":null,"fundName":null}],"partnerCount":3,"partners":[{"id":52609,"name":"Alex Colville","title":"General Partner","seniority":null,"focusTags":[],"linkedinUrl":"https://www.linkedin.com/in/alexcolville","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":52610,"name":"Solo GP","title":"GP","seniority":null,"focusTags":["Longevity","Biotech","Pre-seed"],"linkedinUrl":null,"twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":52608,"name":"Lily Clayton","title":"Director of Operations","seniority":null,"focusTags":[],"linkedinUrl":"https://www.linkedin.com/in/lilyclayton","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]}],"funds":[{"id":1041,"name":"AGE1 Fund I","vintageYear":2020,"sizeUsd":null,"status":"investing","focusAreas":[]}],"activity":{"lastInvestmentYear":null,"investmentsThisYear":0},"activityItems":[{"kind":"fund","title":"Raised AGE1 Fund I","url":null,"source":"fund records","occurredAt":"2020-06-30T00:00:00.000Z"}],"contentUpdatedAt":"2026-10-27T01:50:35.882Z","investorType":"vc","preferredApproach":"cold outreach ok","prefersFounderType":null,"oneClickPitchEnabled":false,"relatedFirms":[{"id":7722,"name":"Sheesha Finance","slug":"sheesha-finance","logoUrl":null,"website":"https://sheeshafinance.gitbook.io/","stageFocus":[],"sectorTags":["AI / ML","Developer Tools","Fintech"],"hqGeo":null},{"id":13762,"name":"NeuroNet Ventures","slug":"neuronet-ventures","logoUrl":null,"website":"https://neuronetgpo.com/","stageFocus":["Seed"],"sectorTags":["AI / ML"],"hqGeo":"Chicago, IL"},{"id":11767,"name":"LiftScale Partners","slug":"liftscale-partners","logoUrl":null,"website":"https://weareliftscale.com/","stageFocus":["Pre-Seed"],"sectorTags":["AI / ML","SaaS"],"hqGeo":"San Francisco, CA"},{"id":11323,"name":"Mountain Pine Capital","slug":"mountain-pine-capital","logoUrl":null,"website":"https://mountainpineholdings.com/","stageFocus":["Seed"],"sectorTags":["Consumer","Healthcare","Real Estate"],"hqGeo":"Salt Lake City, UT"},{"id":1574,"name":"Plaid Ventures","slug":"plaid-ventures","logoUrl":null,"website":"https://plaid.com/","stageFocus":["Pre-Seed","Seed"],"sectorTags":["Fintech","Developer Tools","AI / ML"],"hqGeo":"San Francisco, CA"},{"id":12955,"name":"Jovono","slug":"jovono","logoUrl":null,"website":"https://jovono.com","stageFocus":["Seed","Series A"],"sectorTags":["Climate / Energy","Fintech","Consumer","SaaS","Healthcare"],"hqGeo":"Los Angeles, CA"}],"featuredIn":[{"slug":"pre-seed","displayName":"Pre-Seed Investors","pageType":"stage"},{"slug":"seed","displayName":"Seed Investors","pageType":"stage"},{"slug":"ai","displayName":"AI & ML Investors","pageType":"industry"},{"slug":"healthcare","displayName":"Healthcare Investors","pageType":"industry"},{"slug":"consumer","displayName":"Consumer Investors","pageType":"industry"}],"fundraisingResources":[{"slug":"how-vcs-help-portfolio-raise-follow-on","title":"How VCs Can Actually Help Their Portfolio Companies Raise Follow-On"},{"slug":"how-many-investors-should-you-pitch","title":"How Many Investors Should You Pitch? The Math Most Founders Get Wrong"},{"slug":"what-vcs-actually-look-for-pitch-deck","title":"What VCs Actually Look for in a Pitch Deck"}],"overviewNarrative":null,"portfolioNarrative":null,"seoTitle":null,"seoDescription":null,"lastVerifiedAt":"2026-10-28T06:44:20.275Z"}